Skip to main content

Table 3 Incremental economic outcomes for different OPV cessation timing options compared to the current timing plan based on vaccination costs and expected paralytic polio cases between 2015 and 2019

From: Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes

Alternative Incremental cost-effectiveness ratioa Incremental net benefits ($)
LOW LMI UMI HIGH LOW LMI UMI HIGH All
OPV23 cessation in 2017 CLS CLS CLS CLS 0.3 3.0 2.7 1.3 7.3
OPV123 cessation in 2018 CLS CLS CLS 1.9 300 660 190 −8.6 1,100
OPV123 cessation in 2019 Dominated Dominated Dominated Dominated −0.3 −2.6 −1.6 0 −4.6
OPV123 cessation in 2019 with tOPV-only from 2017 Dominated Dominated Dominated Dominated −0.3 −2.5 −1.6 0 −4.5
OPV123 cessation in 2019 with IPV added from 2018 CSLC CSLC CSLC Dominated 110 370 380 0 860
  1. Abbreviations: HIGH, high-income; IPV, inactivated poliovirus vaccine; LMI, lower middle-income; LOW, low-income; OPV, oral poliovirus vaccine; OPV(##) cessation, globally-coordinated cessation of OPV containing the serotype(s) indicated by ##; UMI, upper middle-income; $, 2013 United States dollar
  2. aNumbers represent millions of $ per disability-adjusted life-year averted; Letters are: CLS, cost and life-saving (i.e., negative incremental costs and positive cases prevented); CSLC cost-saving but life-costing (i.e., positive incremental costs and negative cases prevented); Dominated, positive incremental costs and negative cases prevented